Virginia
Fee-For-Service Medicaid Coverage of Screening
Covered
Highlighted Disparity
Black individuals in Virginia are least likely to receive surgical treatment.
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases is 52.4 and significantly lower than the national rate of 54.6.
- Virginia ranks 16th among all states, placing it in the average tier.
- Over the last five years, the rate of new cases improved by 18%.
5-Year Survival Rate:
- The percent of people still alive five years after being diagnosed with lung cancer (the survival rate) is 26.6% nationally.
- Virginia is one of the 9 states for which survival data is not available as they do not track cases after diagnosis.
Early Diagnosis:
- 25.9% of cases are caught at an early stage, which is significantly lower than the national rate of 26.6%.
- It ranks 31st among the 47 states with data on diagnosis at an early stage, placing it in the average tier.
- Over the last five years, the early diagnosis rate in Virginia improved by 11%.
Lung Cancer Treatment
Surgical Treatment:
- Virginia ranked 22nd (out of the 47 states with available data) with 20.3% of cases undergoing surgery as part of the first course of treatment.
- This is not significantly different than the national rate of 20.8% and puts Virginia in the average tier.
- Over the last five years, the percent of cases undergoing surgery in Virginia did not change significantly.
Lack of Treatment:
- Virginia ranked 8th (out of the 47 states with available data) with 16.9% of cases not receiving any treatment.
- This is significantly lower than the national rate of 20.6% and puts Virginia in the above average tier.
- Over the last five years, the percent of cases receiving no treatment in Virginia improved by 28%.
Screening
Screening for High Risk:
- In Virginia, 7.2% of those at high risk were screened, which was significantly higher than the national rate of 4.5%.
- It ranks 10th among all states, placing it in the above average tier.
- Actual screening rates may be higher in states with large, regional managed care providers that did not share screening data.
Medicaid Coverage:
- Virginia was one of the 49 states whose Medicaid fee-for-service programs covered lung cancer screening as of October 2023.
- While their program did not require prior authorization or copays, it did not use recommended guidelines for determining eligibility.
Prevention
Tobacco Use:
- The smoking rate in Virginia is 12.4% and not significantly different than the national rate of 13.5%.
- It ranks 16th among all states, placing it in the average tier.
Radon:
- In Virginia, 25.2% of radon tests results were at or above the action level recommended by EPA.
- It ranks 28th among all states, placing it in the average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 55.0 per 100,000 population among Black individuals in Virginia, not significantly different than the rate of 56.3 among Black individuals nationally, and not significantly different than the rate of 54.6 among white individuals in Virginia.
- Survival rates by race and ethnicity are not available for Virginia at this time. Nationally, the five-year survival rate among Black individuals is 23.8%, 11% lower than among white Americans.
- 22.5% of lung cancer cases are diagnosed at an early stage among Black individuals in Virginia, not significantly different than the rate of 23.2% among Black individuals nationally, and significantly lower than the rate of 27.0% among white individuals in Virginia.
- 16.6% of Black individuals with lung cancer in Virginia underwent surgery, not significantly different than the rate of 17.0% among Black individuals nationally, and significantly lower than the rate of 21.0% among white individuals in Virginia.
- 18.0% of Black individuals with lung cancer in Virginia did not receive any treatment, significantly lower than the rate of 22.4% among Black individuals nationally, and significantly higher than the rate of 16.7% among white individuals in Virginia.
Latino individuals:
- The rate of new lung cancer cases is 21.2 per 100,000 population among Latino individuals in Virginia, significantly lower than the rate of 28.2 among Latino individuals nationally, and significantly lower than the rate of 54.6 among white individuals in Virginia.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
- 22.1% of lung cancer cases are diagnosed at an early stage among Latino individuals in Virginia, not significantly different than the rate of 23.1% among Latino individuals nationally, and not significantly different than the rate of 27.0% among white individuals in Virginia.
- 22.4% of Latino individuals with lung cancer in Virginia underwent surgery, not significantly different than the rate of 21.6% among Latino individuals nationally, and not significantly different than the rate of 21.0% among white individuals in Virginia.
- 12.7% of Latino individuals with lung cancer in Virginia did not receive any treatment, significantly lower than the rate of 26.1% among Latino individuals nationally, and significantly lower than the rate of 16.7% among white individuals in Virginia.
Asian Americans or Pacific Islanders:
- The rate of new lung cancer cases is 26.0 per 100,000 population among Asian or Pacific Islanders individuals in Virginia, significantly lower than the rate of 32.9 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 54.6 among white individuals in Virginia.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
- 22.6% of lung cancer cases are diagnosed at an early stage among Asian or Pacific Islander individuals in Virginia, not significantly different than the rate of 22.8% among Asian or Pacific Islander individuals nationally, and significantly lower than the rate of 27.0% among white individuals in Virginia.
- 22.8% of Asian or Pacific Islander individuals with lung cancer in Virginia underwent surgery, not significantly different than the rate of 24.7% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 21.0% among white individuals in Virginia.
- 16.0% of Asian or Pacific Islander individuals with lung cancer in Virginia did not receive any treatment, significantly lower than the rate of 20.2% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 16.7% among white individuals in Virginia.
Indigenous Peoples:
- The rate of new lung cancer cases is 22.0 per 100,000 population among Indigenous Peoples (American Indians/Alaska Natives) in Virginia, significantly lower than the rate of 39.4 among Indigenous Peoples nationally, and significantly lower than the rate of 54.6 among white individuals in Virginia.
- State-level survival rates are not available for Indigenous Peoples at this time. Nationally, the five-year survival rate among Indigenous Peoples is 22.3% and not significantly different than the rate of 25.0% among white individuals.
- Other lung cancer rates are not available for Indigenous Peoples (American Indians/Alaska Natives) in Virginia due to too few cases over the time period to allow for accurate analysis.
Summary
Despite the early diagnosis rate in Virginia falling into the average tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
The Lung Association encourages all states to cover lung cancer screening based on the latest guidelines across all fee-for-service and managed care plans without any financial or administrative barriers in their Medicaid programs.
Virginia falls into the above average tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.